Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | HLCS | P50747 | 2/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | PRKCA | P17252 | 2/20 | 0.35 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2780724 | 1.00 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1CYP1A2HLCSS1PR2 | |
| SCHEMBL10337476 | 1.00 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1CYP1A2HLCSS1PR2 | |
| SCHEMBL13082563 | 1.00 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1CYP1A2HLCSS1PR2 | |
| SCHEMBL474085 | 1.00 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1CYP1A2HLCSS1PR2 | |
| SCHEMBL9052248 | 0.98 | ALDH1A1 (0.45) | ALDH1A1L3MBTL1CYP1A2HLCSS1PR2 | |
| SCHEMBL8443031 | 0.98 | ALDH1A1 (0.45) | ALDH1A1L3MBTL1CYP1A2HLCSS1PR2 | |
| SCHEMBL5518415 | 0.98 | ALDH1A1 (0.45) | ALDH1A1L3MBTL1CYP1A2HLCSS1PR2 | |
| SCHEMBL1439579 | 0.85 | — | — | |
| SCHEMBL2365737 | 0.85 | — | — | |
| SCHEMBL1439581 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030129191-A1 | Pretargeting methods and compounds | NEORX CORPORATION (US) | 2003-07-10 | — | — | US | claimed |
| US-6416738-B1 | ADMINISTERING TO A RECIPIENT A FIRST CONJUGATE COMPRISING A TARGETING MOIETY AND A MEMBER OF A LIGAND/ANTI-LIGAND BINDING PAIR, THEREAFTER ADMINISTERING TO THE RECIPIENT A CLEARING AGENT, ADMINISTERING SECOND CONJUGATE | NEORX CORPORATION | 2002-07-09 | — | — | US | claimed |
| US-6075010-A | Small molecular weight ligand-hexose containing clearing agents | NEORX CORPORATION (US) | 2000-06-13 | — | — | US | claimed |
| EP-0743956-A4 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORP (US) | 1999-03-24 | — | — | EP | claimed |
| US-5624896-A | Clearing agents useful in pretargeting methods | NEORX CORPORATION (US) | 1997-04-29 | — | — | US | claimed |
| EP-0743956-A1 | PRETARGETING METHODS AND COMPOUNDS | NeoRx (US) | 1996-11-27 | — | — | EP | claimed |
| WO-1995015978-A1 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1995-06-15 | — | — | WO | claimed |
| US-7060689-B2 | Injection of chemical intermediates into mammalian cells; obtain cells, inject with ligand joined colloid, detect signal from ligand | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-06-13 | — | — | US | disclosed |
| US-6908903-B1 | Cluster clearing agents | ALETHEON PHARMACEUTICALS, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| EP-0906015-A4 | LIVER RETENTION CLEARING AGENTS | NEORX CORP (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20030129191-A1 | Pretargeting methods and compounds | NEORX CORPORATION (US) | 2003-07-10 | — | — | US | disclosed |
| EP-0794788-B1 | HEPATIC-DIRECTED COMPOUNDS AND REAGENTS FOR PREPARATION THEREOF | NEORX CORP (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20020164648-A1 | Injection of chemical intermediates into mammalian cells; obtain cells, inject with ligand joined colloid, detect signal from ligand | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2002-11-07 | — | — | US | disclosed |
| WO-1997046098-A9 | CLUSTER CLEARING AGENTS | — | 1998-08-06 | — | — | WO | disclosed |
| WO-1997046099-A1 | LIVER RETENTION CLEARING AGENTS | NEORX CORPORATION (US) | 1997-12-11 | — | — | WO | disclosed |
| EP-0794788-A1 | HEPATIC-DIRECTED COMPOUNDS AND REAGENTS FOR PREPARATION THEREOF | NEORX CORPORATION (US) | 1997-09-17 | — | — | EP | disclosed |
| US-5624896-A | Clearing agents useful in pretargeting methods | NEORX CORPORATION (US) | 1997-04-29 | — | — | US | disclosed |
| EP-0743956-A1 | PRETARGETING METHODS AND COMPOUNDS | NeoRx (US) | 1996-11-27 | — | — | EP | disclosed |
| WO-1996017613-A1 | HEPATIC-DIRECTED COMPOUNDS AND REAGENTS FOR PREPARATION THEREOF | NEORX CORPORATION (US) | 1996-06-13 | — | — | WO | disclosed |
| WO-1995015978-A1 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030129191-A1 | Pretargeting methods and compounds | BTD, HLCS, STRA6 | ALDH1A1 1840/4885L3MBTL1 1239/4885CYP1A2 4699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.